tirzepatide adolescent obesity trial VisualAbstract: A Randomized, Controlled of Liraglutide for Adolescents with semaglutide adolescent obesity trial 2022

GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging

The FDA is now considering allowing its use in supplements due to its long history of safe use

Retatrutide and tirzepatide both act on GLP-1 and GIP receptors - they overlap heavily on the same pathways

Ruiz RuizJCOrtiz VazquezELSegura CamposMR

10.1016/j.brainres.2011.10.026 93